Skip to Main Content

Paper Details

US Food and Drug Administration regulatory reviewer disagreements and postmarket safety actions among new therapeutics.
BMJ Evid Based Med
0
2023
Author NameAffiliation
Joseph S RossYale School of Medicine
  • 1 - 1

Datasets

Release 1.2